Whether this finding can be replicated in future studies, and what significance it holds for the broader understanding of GLP-1R agonisms effects on food preference, remains to be determined
Clinical implication: clinicians should treat vaginal symptoms in patients taking semaglutide as real and addressable , but approach causality cautiously: prioritise common diagnoses (genitourinary syndrome of menopause, infections, dermatologic vulvar disease, STIs, irritant/contact dermatitis, pelvic floor disorders), identify important confounders (notably SGLT2 inhibitors, antibiotics, hormonal therapies), manage symptoms and underlying conditions, and report suspected adverse reactions when there is a reasonable temporal relationship and alternative causes are less likely
Timeline for Nocatee Patients Month 1: Dramatic appetite reduction, initial loss of 8-15 pounds, adjustment to new eating patterns, confidence building in the process
Serious risks include pancreatitis, thyroid changes, and gallbladder issues
